Preeclampsia, Severe Preeclampsia
Conditions
Brief summary
Preeclampsia is a pregnancy complication characterized by high blood pressure associated with damage to various organs, especially the kidneys. It happens in about 1 to 5% of pregnant women and can cause serious problems for both the mother and the baby. Several multi-omics studies have already been conducted on preeclampsia, with promising results. However, this is preliminary data that requires further studies. The molecular markers identified in this type of study could potentially be used, first of all, for the early screening of this condition, which is not yet reliably achievable. In addition, the knowledge gained from this research would help us better understand the pathophysiology of preeclampsia. Therefore, the investigators' goal is to carry out a multi-omics analysis of preeclampsia to uncover the genetic and molecular mechanisms involved in this condition.
Detailed description
This study is a cross-sectional, prospective, comparative, and single-center study. It compares a group of 50 pregnant women with severe preeclampsia to a control group of 50 pregnant women without any pathology.
Interventions
None listed
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
Inclusion criteria for patients in the experimental group P: \- Pregnant women between 18 and 45 years old, between 24 and 41 weeks of amenorrhea (WA), with severe preeclampsia defined according to the criteria of the joint expert recommendations of the French National College of Gynecologists and Obstetricians (CNGOF) and the French Society of Anesthesia and Intensive Care (SFAR) from 2020 "Management of the patient with severe preeclampsia." These criteria are: gestational hypertension with systolic ≥ 140 mmHg and/or diastolic ≥ 90 mmHg, and proteinuria ≥ 0.3g/24h, plus at least one of the following severity criteria: * Severe hypertension (SBP ≥ 160 mmHg and/or DBP ≥ 110 mmHg) or uncontrolled. * Proteinuria \> 3g/24h. * Creatinine ≥ 90 μmol/L. * Oliguria ≤ 500 mL/24h or ≤ 25 mL/h. * Thrombocytopenia \< 100,000/mm3 * Liver enzyme elevation with AST/ALT \>2x normal. * Epigastric abdominal pain and/or persistent or severe right upper quadrant pain "like a band." * Chest pain, shortness of breath, acute pulmonary edema. * Neurological signs: severe headaches not responding to treatment, persistent visual or auditory disturbances, hyperactive, widespread, and polykinetic tendon reflexes. * Patient's free and informed consent regarding the collection of maternal blood and urine. * Consent from both legal guardians regarding the collection of cord blood, placenta samples, and newborn data. Inclusion criteria for patients in the control group: * Pregnant women between 18 and 45 years old and between 24 and 41 weeks of gestation, with a pregnancy without any complications * Free and informed consent from the patient regarding the collection of maternal blood and urine * Consent from both holders of parental authority regarding the collection of cord blood, placental fragments, and newborn data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identifying genetic and molecular markers associated with severe forms of preeclampsia | At enrollment | Identify, from blood, urine, and placental samples, the changes in genetic and molecular signatures as well as in cell composition associated with severe forms of preeclampsia, by comparing the expression levels of the signatures and the relative abundance of different cell populations between patients with severe preeclampsia and control patients. |
Contacts
CONTACTMme STOERKEL Johanne
Outcome results
None listed